ReviewCell and tissue research2012
Endogenous tissue engineering: PTH therapy for skeletal repair.
Review in Cell and tissue research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Signaling Pathways Driving MSC Osteogenesis: Mechanisms, Regulation, and Translational Applications.International journal of molecular sciences · 2025Review
- Differential bone and vessel type formation at superior and dura periosteum during cranial bone defect repair.Bone research · 2025Article
- Advantages of Material Biofunctionalization Using Nucleic Acid Aptamers in Tissue Engineering and Regenerative Medicine.Molecular biotechnology · 2023Review
- Early protection against bone stress injuries by mobilization of endogenous targeted bone remodeling.iScience · 2023Article
- PTHrP promotes subchondral bone formation in TMJ-OA.International journal of oral science · 2022Article
- Synthetic materials in craniofacial regenerative medicine: A comprehensive overview.Frontiers in bioengineering and biotechnology · 2022Review
- Matrix metalloproteinase (MMP)-degradable tissue engineered periosteum coordinates allograft healing via early stage recruitment and support of host neurovasculature.Biomaterials · 2021Article
- Building Complex Life Through Self-Organization.Tissue engineering. Part A · 2019Review
- Optimal administration frequency and dose of teriparatide for acceleration of biomechanical healing of long-bone fracture in a mouse model.Journal of bone and mineral metabolism · 2019Article
- Triweekly administration of parathyroid hormone (1-34) accelerates bone healing in a rat refractory fracture model.BMC musculoskeletal disorders · 2017Article
- Oleanolic Acid Enhances Mesenchymal Stromal Cell Osteogenic Potential by Inhibition of Notch Signaling.Scientific reports · 2017Article
- Effects of Intermittent Administration of Parathyroid Hormone (1-34) on Bone Differentiation in Stromal Precursor Antigen-1 Positive Human Periodontal Ligament Stem Cells.Stem cells international · 2016Article
- Identification and Characterization of a Synthetic Osteogenic Peptide.Calcified tissue international · 2015Article
- Emulating native periosteum cell population and subsequent paracrine factor production to promote tissue engineered periosteum-mediated allograft healing.Biomaterials · 2015Article
- The effect of mesenchymal stem cells delivered via hydrogel-based tissue engineered periosteum on bone allograft healing.Biomaterials · 2013Article
- Emerging ideas: Engineering the periosteum: revitalizing allografts by mimicking autograft healing.Clinical orthopaedics and related research · 2013Article
- Quantifying massive allograft healing of the canine femur in vivo and ex vivo: a pilot study.Clinical orthopaedics and related research · 2012Article
- Inflammatory bone loss: pathogenesis and therapeutic intervention.Nature reviews. Drug discovery · 2012Review
- Interplay of Nkx3.2, Sox9 and Pax3 regulates chondrogenic differentiation of muscle progenitor cells.PloS one · 2012Article
- PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Based on its proven anabolic effects on bone in osteoporosis patients, recombinant parathyroid hormone (PTH(1-34)) has been evaluated as a potential therapy for skeletal repair. In animals, the effect of PTH(1-34) has been investigated in various skeletal repair models such as fractures, allografting, spinal arthrodesis and distraction osteogenesis. These studies have demonstrated that intermittent PTH(1-34) treatment enhances and accelerates the skeletal repair process via a number of mechanisms, which include effects on mesenchymal stem cells, angiogenesis, chondrogenesis, bone formation and resorption. Furthermore, PTH(1-34) has been shown to enhance bone repair in challenged animal models of aging, inflammatory arthritis and glucocorticoid-induced bone loss. This pre-clinical success has led to off-label clinical use and a number of case reports documenting PTH(1-34) treatment of delayed-unions and non-unions have been published. Although a recently completed phase 2 clinical trial of PTH(1-34) treatment of patients with radius fracture has failed to achieve its primary outcome, largely because of effective healing in the placebo group, several secondary outcomes are statistically significant, highlighting important issues concerning the appropriate patient population for PTH(1-34) therapy in skeletal repair. Here, we review our current knowledge of the effects of PTH(1-34) therapy for bone healing, enumerate several critical unresolved issues (e.g., appropriate dosing regimen and indications) and discuss the long-term potential of this drug as an adjuvant for endogenous tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.